ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31

Zomedica Corp.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$0.08−0.00 (-0.55%)

Close on Oct 19, 2026

Market cap: $77.40M
P/E (TTM): –
Dividend yield: –

Zomedica Corp. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31
Revenue	37	34	32	29	28	28	27	27	26	26	25	24	22	21	19	17	12	7.87	4.13	0.05	0.03	0.01	0	–	–	–	–	–	–	–	–	–	–	–	–
Cost of Revenue	13	12	10	9.40	8.68	8.15	8.20	8.12	8.16	8.37	7.87	7.55	6.83	6.10	5.46	4.54	3.29	2.09	1.08	0.06	0.04	0.01	0	–	–	–	–	–	–	–	–	–	–	–	–
Gross Profit	24	23	22	20	20	19	19	19	18	18	17	16	16	15	13	12	8.81	5.79	3.05	-0.01	-0.01	0.01	0	–	–	–	–	–	–	–	–	–	–	–	–
Research & Development	5.65	6.47	7.17	7.67	7.73	7.35	7.27	8.22	7.24	6.60	5.74	3.34	3.69	3.15	2.58	2.55	1.62	1.58	1.67	1.81	4.22	7.86	8.04	8.03	6.29	3.44	10	16	16	17	10	4.93	4.77	2.74	2.75
Selling, General & Admin	39	41	43	44	44	45	47	49	47	45	43	38	38	37	33	32	30	26	23	18	14	10	8.72	–	–	–	–	–	–	–	–	–	–	–	–
Selling & Marketing	16	17	19	19	19	18	17	16	16	15	14	–	–	–	9.88	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	23	24	24	25	25	27	30	32	32	31	29	–	–	–	23	–	–	–	–	–	–	–	6.01	5.07	5.11	5.02	6.99	6.77	6.23	6.57	4.52	4.26	4.78	4.28	3.95
Operating Income	-21	-25	-84	-87	-88	-105	-51	-66	-64	-46	-43	-25	-26	-25	-22	-23	-22	-22	-21	-20	-18	-18	-17	-15	-13	-10	-20	-25	-24	-26	-17	-11	-11	-8.41	-8.08
Interest Expense	–	–	–	–	–	–	–	–	–	–	0.18	–	–	–	–	–	–	–	0.01	–	–	–	0.00	0.00	0.00	0.01	0.02	–	–	–	–	–	–	–	–
Income from Equity Investments	-0.13	-0.13	-0.14	-0.14	-0.16	–	-0.16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-0.13	-0.13	-0.14	-0.11	-0.21	-0.12	0.01	-0.09	2.22	2.16	2.08	2.20	-0.01	0.00	-0.01	-0.48	-0.48	0.03	0.05	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	46	46	56	56	1,997	16	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.08	-0.08	-0.07	-0.08	-0.18	-0.23	-0.21	-0.16	-0.02	0.04	0.02	–	–	–	0.00	0.02	-0.01	-0.01	-0.25	-0.50	-0.47	-0.47	-0.12	-0.13	-0.13	-0.13	0.00	–	–	–	-0.07	–	–	–	–
Pretax Income	-19	-23	-82	-85	-85	-102	-48	-62	-58	-39	-36	-18	-21	-21	-19	-21	-22	-21	-21	-19	-18	-18	-17	-16	-13	-11	-20	-25	-24	-26	-17	-11	-11	-8.40	-8.07
Income Tax Expense	-0.17	-0.18	-0.28	-0.29	-0.29	-0.45	-0.56	0.12	-1.77	-1.70	-1.33	-2.84	-1.58	-1.88	-2.37	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-19	-23	-82	-85	-85	-102	-47	-62	-56	-37	-35	-15	-19	-19	-17	-17	-19	-18	-18	-19	-18	-18	-17	-16	-13	-11	-20	-25	-24	-26	-17	-11	-11	-8.40	-8.07
EPS (Basic)(per share)	-0.01	-0.02	-0.08	-0.10	-0.10	-0.11	-0.05	-0.06	-0.05	-0.04	-0.04	-0.01	-0.02	-0.02	-0.02	-0.01	-0.02	-0.02	-0.05	-0.06	-0.07	-0.08	-0.05	-0.08	-0.10	-0.10	-0.19	-0.26	-0.25	-0.27	-0.18	-0.11	-0.11	-0.09	-0.09
EPS (Diluted)(per share)	-0.01	-0.02	-0.08	-0.10	-0.10	-0.11	-0.05	-0.06	-0.05	-0.04	-0.04	-0.01	-0.02	-0.02	-0.02	-0.01	-0.02	-0.02	-0.05	-0.06	-0.07	-0.08	-0.05	-0.08	-0.10	-0.10	-0.19	-0.26	-0.25	-0.27	-0.18	-0.11	-0.11	-0.09	-0.09
Shares Outstanding (Basic, Weighted)(shares)	980	980	980	980	980	980	980	980	980	980	980	980	980	980	980	980	980	978	957	857	750	560	364	248	137	111	106	103	100	96	93	92	90	89	87
Shares Outstanding (Diluted, Weighted)(shares)	980	980	980	980	980	980	980	980	980	980	980	980	980	980	980	980	980	978	957	857	750	560	364	248	137	111	106	103	100	96	93	92	90	89	87
EBITDA	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-16	-15	-13	-10	-20	-25	-24	-26	-16	–	–	–	–
Total Interest Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.70	–	–	–	0.36	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 65.4%
Operating margin: -56.3%
Net margin: -51.4%
Return on equity, FY2025: -52.6%

Financial strength

Current ratio: 6.43
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 79.9%

Valuation

P/E ratio: –
Price to sales: 2.10
Price to book: 0.72
Dividend yield: –